Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Adipose-Derived Mesenchymal Stem Cells for Liver Cirrhosis
jRCTb010250024Recruiting
- Sponsor
- Medinet
- Start
- Jul 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in Cirrhosis, sponsored by Medinet. Primary endpoint: Safety. Started Jul 2025; status: recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCTb010250024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb010250024.